JAK1 and graft versus host disease: Shortly after, Ruxolitinib (INCB018424), a bioavailable JAK1/2 inhibitor, was reported to have similar mitigating effects on GVHD as IFNγR-/- T cells while the GvL effect was preserved (176, 177, 221, 222).